Cargando…

Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation

The implementation of high-dose posttransplantation cyclophosphamide (PTCy) has made HLA-haploidentical (haplo) blood or marrow transplantation (BMT) a cost effective and safe alternative donor transplantation technique, resulting in its increasing utilization over the last decade. We review the ava...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCurdy, Shannon R., Fuchs, Ephraim J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680052/ https://www.ncbi.nlm.nih.gov/pubmed/26713094 http://dx.doi.org/10.1155/2015/431923

Ejemplares similares

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation
por: Williams, Louis, et al.
Publicado: (2020)

Loss of the Mismatched Human Leukocyte Antigen Haplotype in Two Acute Myelogenous Leukemia Relapses after Haploidentical Bone Marrow Transplantation with Posttransplantation Cyclophosphamide
por: McCurdy, Shannon R., et al.
Publicado: (2016)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients
por: Lu, Wenyi, et al.
Publicado: (2022)

Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies
por: Gu, Zhenyang, et al.
Publicado: (2017)

Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders
por: Albert, Michael H., et al.
Publicado: (2021)

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
por: Chang, Ying-Jun, et al.
Publicado: (2016)

A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform
por: Mayumi, Hisanori
Publicado: (2021)

A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation
por: Lee, Myung-Won, et al.
Publicado: (2020)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide
por: Muñiz, Paula, et al.
Publicado: (2021)

Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2020)

A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies
por: Nakamae, Hirohisa, et al.
Publicado: (2022)

PB2190: HLA-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER REDUCED-INTENSITY CONDITIONING
por: Kim, J., et al.
Publicado: (2022)

Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
por: Weng, Guangyang, et al.
Publicado: (2022)

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies
por: Solh, Melhem M., et al.
Publicado: (2021)

Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide
por: Maeda, Yoshinobu
Publicado: (2021)

Haploidentical Stem Cell Transplantation: A Gateway to Infrequent Availability of HLA-Matched Related Donors
por: Aslam, Hafiz Muhammad, et al.
Publicado: (2018)

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
por: Bacigalupo, Andrea, et al.
Publicado: (2016)

Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide
por: Kanakry, Christopher G., et al.
Publicado: (2017)

Autoimmune Limbic Encephalitis in Patients with Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
por: Heo, Bu Yeon, et al.
Publicado: (2023)

Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2023)

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation
por: Wada, Fumiya, et al.
Publicado: (2023)

Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: A meta-analysis
por: Chen, Dangui, et al.
Publicado: (2018)

Brain toxoplasmosis after HLA haploidentical transplantation for acute myeloid leukemia
por: Tsushima, Takafumi, et al.
Publicado: (2022)

Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS
por: Michel, Claire, et al.
Publicado: (2023)

Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I
por: Yamashita, Motoi, et al.
Publicado: (2022)

Unmanipulated haploidentical transplantation for adult patients with hematological malignancies
por: Ruggeri, Annalisa, et al.
Publicado: (2019)

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
por: Castagna, Luca, et al.
Publicado: (2020)

T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients
por: Sodani, Pietro, et al.
Publicado: (2011)

HLA Alleles Cw12 and DQ4 in Kidney Transplant Recipients Are Independent Risk Factors for the Development of Posttransplantation Diabetes
por: Phagura, Nuvreen, et al.
Publicado: (2021)

Analysis of the Influence of HLA-A Matching Relative to HLA-B and -DR Matching on Heart Transplant Outcomes
por: Ansari, David, et al.
Publicado: (2015)

Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants
por: Bacigalupo, Andrea
Publicado: (2022)

Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies
por: Fabricius, William A., et al.
Publicado: (2016)

PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis
por: Haebe, Sarah, et al.
Publicado: (2023)

CD4(+)FOXP3(+) Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2019)

Reflections on HLA Epitope-Based Matching for Transplantation
por: Duquesnoy, Rene J.
Publicado: (2016)

Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?
por: Perales, Miguel-Angel, et al.
Publicado: (2020)

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
por: Rieger, Max J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v3erq51tracbq0mpeir0e0tstv